Search
Cefotiam
go.drugbank.com/drugs/DB00229ApprovedOne of the cephalosporins that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms.
Cephaloglycin
go.drugbank.com/drugs/DB00689ApprovedA cephalorsporin antibiotic that is no longer commonly used.
Ceforanide
go.drugbank.com/drugs/DB00923ApprovedCeforanide is administered parenterally. It has a longer elimination half-life than any currently available cephalosporin. Its activity is very similar to that of cefamandole, another second-generation cephalosporin antibiotic, except th...
Argatroban
go.drugbank.com/drugs/DB00278ApprovedInvestigationalArgatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoi...
Adagrasib
go.drugbank.com/drugs/DB15568ApprovedInvestigationalAdagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. … [L44361,L44366] Adagrasib joins [sotorasib] as another KRAS<sup>G12C</sup> inhibitor approved by the FDA.[A254062]
Carglumic acid
go.drugbank.com/drugs/DB06775ApprovedInvestigationalCarglumic acid was approved by the U.S. Food and Drug Administration (FDA) on 18 March 2010.
Pemigatinib
go.drugbank.com/drugs/DB15102ApprovedInvestigationalgrowth factor receptor 2 (FGFR2) gene fusion or other rearrangements as detected by an FDA-approved test. … It works by inhibiting fibroblast growth factor receptors (FGFRs), which are receptor tyrosine kinases that activate signalling pathways in tumour cells.
Nonacog beta pegol
go.drugbank.com/drugs/DB13933ApprovedInvestigational[A31496] Nonacog beta pegol was developed by Novo Nordisk and received its first global approval by the FDA on May 31, 2017,[L1098] followed by the European Commission approval on June 2, 2017. … [L41185] Nonacog beta pegol was approved by Health Canada on November 29, 2017.[L43682]
Pizotifen
go.drugbank.com/drugs/DB06153ApprovedSandomigran is available in a number of countries but is not approved by the FDA nor EMA.
Sacituzumab govitecan
go.drugbank.com/drugs/DB12893ApprovedInvestigational[A193653] In November 2021 and July 20 2023, sacituzumab govitecan was also approved by the European Commission and Health Canada respectively.[L39372,L47601] … [L13002, A193674] Sacituzumab govitecan was granted FDA approval on April 22nd, 2020 and is marketed under the brand name Trodelvy™ by Immunomedics, Inc.; it is currently indicated under accelerated